|
시장보고서
상품코드
2050775
생물제제 시장 : 제품별, 약제 분류별, 투여 경로별, 구입 형태별, 유통 채널별, 지역별Biologics Market, By Product, By Drug Classification, By Route of Administration, By Mode of Purchase, By Distribution Channel,By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
바이오의약품 시장은 2026년에 6억 3,990만 달러로 추계되고 있으며, 2033년까지 13억 1,180만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 10.8%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 6억 3,990만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 10.80% | 2033년 시장 규모 예측 : | 13억 1,180만 달러 |
바이오의약품은 인간의 질병을 예방, 치료 및 치유하는 데 사용되는 생물 유래 의약품을 말합니다. 여기에는 백신, 혈액제제, 알레르겐 제제, 체세포, 유전자치료제, 조직 및 재조합 치료용 단백질이 포함됩니다. 전 세계 만성질환 유병률 증가와 더불어 각종 질병에 취약한 고령 인구의 증가는 바이오의약품의 수요를 증가시킬 수 있습니다. 생명공학 분야의 급속한 혁신과 발전으로 안전성, 유효성 및 작용의 특이성이 개선된 새로운 생물제제의 개발이 가능해졌습니다. 이를 통해 암, 류마티스 질환, 자가면역질환 등 생명을 위협하는 여러 질환에 대한 치료 옵션이 확대되었습니다. 생물제제의 규제 승인 증가와 상업화 진전이 시장 성장을 촉진할 수 있습니다.
시장 역학
세계의 바이오의약품 시장의 성장은 당뇨병, 암, 심혈관 질환 등 만성질환의 전 세계 유병률 증가와 더불어 바이오의약품 연구개발에 대한 헬스케어 비용 증가에 의해 주도되고 있습니다. 단백질 기반 의약품에 대한 수요 증가, 첨단 바이오의약품의 신속한 승인, 강력한 바이오 신약 후보물질 파이프라인도 시장 성장을 촉진하는 요인으로 작용할 것으로 보입니다. 바이오 공정 및 품질 분석 분야의 끊임없는 기술 발전으로 상업적 규모의 비용 효율적인 바이오의약품 생산에 적합한 고수율 생산 플랫폼을 개발할 수 있게 되었습니다. 그러나 바이오 제조 시설 설립에 필요한 막대한 설비 투자, 엄격한 규제 기준, 생체 분자의 복잡성 등이 바이오시밀러 개발의 걸림돌로 작용하고 있습니다. 아시아태평양과 라틴아메리카 등 개발도상국의 신흥 시장은 이해관계자들에게 새로운 지역 시장을 개발하고 이러한 제약의 영향을 상쇄할 수 있는 기회를 제공하고 있습니다.
본 조사의 주요 특징
- 이 보고서는 각 부문의 잠재적 매출기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 시장 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택한 경쟁 전략에 대한 중요 인사이트를 제공합니다.
- 본 조사에서는 다음과 같은 매개변수를 바탕으로 글로벌 바이오의약품 시장의 주요 기업 개요을 작성했습니다. 구체적으로 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적 및 전략 등입니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 등급 향상, 시장 확대 및 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것으로 기대됩니다.
- 이 세계의 바이오로직스 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 글로벌 바이오의약품 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 쉽게 의사결정을 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 생물제제 시장 : 제품별, 2021-2033년
제5장 세계의 생물제제 시장 : 약제 분류별, 2021-2033년
제6장 세계의 생물제제 시장 : 투여 경로별, 2021-2033년
제7장 세계의 생물제제 시장 : 구입 형태별, 2021-2033년
제8장 세계의 생물제제 시장 : 유통 채널별, 2021-2033년
제9장 세계의 생물제제 시장 : 지역별, 2021-2033년
제10장 경쟁 구도
제11장 참고 문헌 및 조사 방법
KSA 26.06.10Biologics Market is estimated to be valued at USD 639.9 Mn in 2026 and is expected to reach USD 1,311.8 Mn by 2033, growing at a compound annual growth rate (CAGR) of 10.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 639.9 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 10.80% | 2033 Value Projection: | USD 1,311.8 Mn |
Biologics refers to medicines created from living organisms that are used to prevent, treat, and cure human diseases. These include vaccines, blood components, allergenics, somatic cells, gene therapies, tissues, and recombinant therapeutic proteins. Increasing prevalence of chronic diseases worldwide coupled with rising elderly population prone to various illnesses can boost demand for biologics. Rapid innovations and advancements in biotechnology have enabled development of novel biologic agents with improved safety, efficacy and specificity of action. This has expanded treatment options for several life threatening conditions such as cancer, rheumatic disorders, and autoimmune diseases. Growing regulatory approvals and commercialization of biologics can drive the market growth.
Market Dynamics
Global biologics market growth is driven by growing prevalence of chronic diseases worldwide such as diabetes, cancer, cardiovascular diseases along with rising healthcare expenditure on biopharmaceutical R&D. Increasing demand for protein based drugs, rapid approvals of advanced biologics and strong pipeline of novel biologic candidates can also drive the market growth. Constant technological advancements in bioprocessing and quality analytics enables development of high yield production platforms conducive for cost effective manufacturing of biologics at commercial scale. However, factors such as high capital investment needs for setting up bio manufacturing facilities, stringent regulatory norms, and complexity of biological molecules poses challenges in biosimilar development. Emerging markets across developing regions such as Asia Pacific and Latin America offer lucrative opportunities for stakeholders to tap into new geographic territories and offset restraint impact.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global biologics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include F. Hoffmann La Roche Ltd., AbbVie Inc., Amgen Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer Inc., Sanofi S.A., Gilead Sciences, Inc., Novartis AG, Bristol Myers Squibb Company, Regeneron Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Eli Lilly and Company, and Celltrion Healthcare Co., Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up gradation, market expansion, and marketing tactics.
- Global biologics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global biologics market.
Market Segmentation
- By Product Insights (Revenue, USD Mn, 2021 - 2033)
- Monoclonal Antibodies
- Vaccines
- Recombinant Hormones/Proteins
- Cellular-based Biologics
- Gene-based Biologics
- Others
- By Drug Classification Insights (Revenue, USD Mn, 2021 - 2033)
- Branded Drugs
- Generic Drugs
- By Route of Administration Insights (Revenue, USD Mn, 2021 - 2033)
- Oral
- Parenteral
- Other Routes
- By Mode of Purchase Insights (Revenue, USD Mn, 2021 - 2033)
- Prescription-Based Drugs
- Over-The-Counter Drugs
- By Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- F. Hoffmann-La Roche Ltd.
- AbbVie Inc.
- Amgen Inc.
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Pfizer Inc.
- Sanofi S.A.
- Gilead Sciences, Inc.
- Novartis AG
- Bristol-Myers Squibb Company
- Regeneron Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
- Biogen Inc.
- Eli Lilly and Company
- Celltrion Healthcare Co., Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Biologics Market, By Product
- Global Biologics Market, By Drug Classification
- Global Biologics Market, By Route of Administration
- Global Biologics Market, By Mode of Purchase
- Global Biologics Market, By Distribution Channel
- Global Biologics Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Biologics Market, By Product, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Recombinant Hormones/Proteins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Cellular-based Biologics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Gene-based Biologics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
5. Global Biologics Market, By Drug Classification, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Branded Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Generic Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
6. Global Biologics Market, By Route of Administration, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Other Routes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
7. Global Biologics Market, By Mode of Purchase, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Prescription-Based Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Over-The-Counter Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
8. Global Biologics Market, By Distribution Channel, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
9. Global Biologics Market, By Region, 2021 - 2033, (USD Mn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2033, (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Product, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Drug Classification, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Mode of Purchase, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Product, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Drug Classification, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Mode of Purchase, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Product, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Drug Classification, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Mode of Purchase, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Product, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Drug Classification, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Mode of Purchase, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Product, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Drug Classification, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Mode of Purchase, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Product, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Drug Classification, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Mode of Purchase, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, (USD Mn)
- South Africa
- North Africa
- Central Africa
10. Competitive Landscape
- Hoffmann-La Roche Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson Services, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gilead Sciences, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Regeneron Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Biogen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Celltrion Healthcare Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
11. References and Research Methodology
- References
- Research Methodology
- About us
